2020
Drápela, Stanislav; Khirsariya, Prashant; Weerden, Wytske M.; Fedr, Radek; Suchánková, Tereza; Búzová, Diana; Červený, Jan; Hampl, Aleš; Puhr, Martin; Watson, William R.; Culig, Zoran; Krejčí, Lumír; Paruch, Kamil; Souček, Karel
In: Molecular oncology, vol. 14, no. 10, pp. 2487–2503, 2020, ISSN: 1878-0261 1574-7891, (Place: United States).
Abstract | Links | BibTeX | Tags: *Mitosis/drug effects, Animals, castration-resistant prostate cancer, Cell Death/drug effects, Cell Line, Cell Proliferation/drug effects, Checkpoint Kinase 1, Checkpoint Kinase 1/*antagonists & inhibitors/metabolism, Deoxycytidine/*analogs & derivatives/pharmacology, Docetaxel resistance, Docetaxel/*pharmacology, Drug resistance, gemcitabine, Humans, Male, Mice, mitotic catastrophe, MU380, Neoplasm/*drug effects, Piperidines/chemistry/*pharmacology, Prostatic Neoplasms/*pathology, Pyrazoles/chemistry/*pharmacology, Pyrimidines/chemistry/*pharmacology, S Phase/drug effects, SCID, Tumor, Xenograft Model Antitumor Assays
@article{drapela_chk1_2020,
title = {The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe.},
author = {Stanislav Drápela and Prashant Khirsariya and Wytske M. Weerden and Radek Fedr and Tereza Suchánková and Diana Búzová and Jan Červený and Aleš Hampl and Martin Puhr and William R. Watson and Zoran Culig and Lumír Krejčí and Kamil Paruch and Karel Souček},
doi = {10.1002/1878-0261.12756},
issn = {1878-0261 1574-7891},
year = {2020},
date = {2020-10-01},
journal = {Molecular oncology},
volume = {14},
number = {10},
pages = {2487–2503},
abstract = {As treatment options for patients with incurable metastatic castration-resistant prostate cancer (mCRPC) are considerably limited, novel effective therapeutic options are needed. Checkpoint kinase 1 (CHK1) is a highly conserved protein kinase implicated in the DNA damage response (DDR) pathway that prevents the accumulation of DNA damage and controls regular genome duplication. CHK1 has been associated with prostate cancer (PCa) induction, progression, and lethality; hence, CHK1 inhibitors SCH900776 (also known as MK-8776) and the more effective SCH900776 analog MU380 may have clinical applications in the therapy of PCa. Synergistic induction of DNA damage with CHK1 inhibition represents a promising therapeutic approach that has been tested in many types of malignancies, but not in chemoresistant mCRPC. Here, we report that such therapeutic approach may be exploited using the synergistic action of the antimetabolite gemcitabine (GEM) and CHK1 inhibitors SCH900776 and MU380 in docetaxel-resistant (DR) mCRPC. Given the results, both CHK1 inhibitors significantly potentiated the sensitivity to GEM in a panel of chemo-naïve and matched DR PCa cell lines under 2D conditions. MU380 exhibited a stronger synergistic effect with GEM than clinical candidate SCH900776. MU380 alone or in combination with GEM significantly reduced spheroid size and increased apoptosis in all patient-derived xenograft 3D cultures, with a higher impact in DR models. Combined treatment induced premature mitosis from G1 phase resulting in the mitotic catastrophe as a prestage of apoptosis. Finally, treatment by MU380 alone, or in combination with GEM, significantly inhibited tumor growth of both PC339-DOC and PC346C-DOC xenograft models in mice. Taken together, our data suggest that metabolically robust and selective CHK1 inhibitor MU380 can bypass docetaxel resistance and improve the effectiveness of GEM in DR mCRPC models. This approach might allow for dose reduction of GEM and thereby minimize undesired toxicity and may represent a therapeutic option for patients with incurable DR mCRPC.},
note = {Place: United States},
keywords = {*Mitosis/drug effects, Animals, castration-resistant prostate cancer, Cell Death/drug effects, Cell Line, Cell Proliferation/drug effects, Checkpoint Kinase 1, Checkpoint Kinase 1/*antagonists & inhibitors/metabolism, Deoxycytidine/*analogs & derivatives/pharmacology, Docetaxel resistance, Docetaxel/*pharmacology, Drug resistance, gemcitabine, Humans, Male, Mice, mitotic catastrophe, MU380, Neoplasm/*drug effects, Piperidines/chemistry/*pharmacology, Prostatic Neoplasms/*pathology, Pyrazoles/chemistry/*pharmacology, Pyrimidines/chemistry/*pharmacology, S Phase/drug effects, SCID, Tumor, Xenograft Model Antitumor Assays},
pubstate = {published},
tppubtype = {article}
}
2011
Trilecová, Lenka; Krčková, Simona; Marvanová, Soňa; Pĕnčíková, Kateřina; Krčmář, Pavel; Neča, Jiří; Hulinková, Petra; Pálková, Lenka; Ciganek, Miroslav; Milcová, Alena; Topinka, Jan; Vondráček, Jan; Machala, Miroslav
Toxic effects of methylated benzo[a]pyrenes in rat liver stem-like cells. Journal Article
In: Chemical research in toxicology, vol. 24, no. 6, pp. 866–876, 2011, ISSN: 1520-5010 0893-228X, (Place: United States).
Abstract | Links | BibTeX | Tags: Animals, Apoptosis/drug effects, Aryl Hydrocarbon/*metabolism, Benzo(a)pyrene/*chemistry/*toxicity, Cell Cycle/drug effects, Cell Line, Checkpoint Kinase 1, DNA Adducts/metabolism, Epithelial Cells/drug effects/metabolism, Gene Expression Regulation/drug effects, Liver/*cytology, Methylation, Mutagens/*chemistry/*toxicity, Oxidative Stress/drug effects, Protein Kinases/metabolism, Rats, Receptors, Stem Cells/drug effects/metabolism, Tumor, Tumor Suppressor Protein p53/metabolism
@article{trilecova_toxic_2011,
title = {Toxic effects of methylated benzo[a]pyrenes in rat liver stem-like cells.},
author = {Lenka Trilecová and Simona Krčková and Soňa Marvanová and Kateřina Pĕnčíková and Pavel Krčmář and Jiří Neča and Petra Hulinková and Lenka Pálková and Miroslav Ciganek and Alena Milcová and Jan Topinka and Jan Vondráček and Miroslav Machala},
doi = {10.1021/tx200049x},
issn = {1520-5010 0893-228X},
year = {2011},
date = {2011-06-01},
journal = {Chemical research in toxicology},
volume = {24},
number = {6},
pages = {866–876},
abstract = {The methylated benzo[a]pyrenes (MeBaPs) are present at significant levels in the environment, especially in the sediments contaminated by petrogenic PAHs. However, the existing data on their toxic effects in vitro and/or in vivo are still largely incomplete. Transcription factor AhR plays a key role in the metabolic activation of PAHs to genotoxic metabolites, but the AhR activation may also contribute to the tumor promoting effects of PAHs. In this study, the AhR-mediated activity of five selected MeBaP isomers was estimated in the DR-CALUX reporter gene assay performed in rat hepatoma cells. Detection of other effects, including induction of CYP1A1, CYP1B1, and AKR1C9 mRNAs, DNA adduct formation, production of reactive oxygen species, oxidation of deoxyguanosine, and cell cycle modulation and apoptosis, was performed in the rat liver epithelial WB-F344 cell line, a model of liver progenitor cells. We identified 1-MeBaP as the most potent inducer of AhR activation, stable DNA adduct formation, checkpoint kinase 1 and p53 phosphorylation, and apoptosis. These effects suggest that 1-MeBaP is a potent genotoxin eliciting a typical sequence of events ascribed to carcinogenic PAHs: induction of CYP1 enzymes, formation of high levels of DNA adducts, activation of DNA damage responses (including p53 phosphorylation), and cell death. In contrast, 10-MeBaP, representing BaP isomers substituted with the methyl group in the angular ring, elicited only low levels DNA adduct formation and apoptosis. Other MeBaPs under study also elicited strong apoptotic responses associated with DNA adduct formation as the prevalent mode of toxic action of these compounds in liver cells. MeBaPs induced a weak production of ROS, which did not lead to significant oxidative DNA damage. Importantly, 1-MeBaP and 3-MeBaP were found to be potent AhR agonists, one order of magnitude more potent than BaP, thus suggesting that the AhR-dependent modulations of gene expression, deregulation of cell survival mechanisms, and further nongenotoxic effects associated with AhR activation may further contribute to their tumor promotion and carcinogenicity.},
note = {Place: United States},
keywords = {Animals, Apoptosis/drug effects, Aryl Hydrocarbon/*metabolism, Benzo(a)pyrene/*chemistry/*toxicity, Cell Cycle/drug effects, Cell Line, Checkpoint Kinase 1, DNA Adducts/metabolism, Epithelial Cells/drug effects/metabolism, Gene Expression Regulation/drug effects, Liver/*cytology, Methylation, Mutagens/*chemistry/*toxicity, Oxidative Stress/drug effects, Protein Kinases/metabolism, Rats, Receptors, Stem Cells/drug effects/metabolism, Tumor, Tumor Suppressor Protein p53/metabolism},
pubstate = {published},
tppubtype = {article}
}